

OCT 15 2002

PATENTS &amp; TRADEMARKS

Please type a plus sign (+) inside this box → +

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

1614

TELE FAX

PTO SB 21-08-04  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE  
Approved for use through 10/31/02. OMB 0651-0031TRANSMITTAL  
FORM

(To be used for all correspondence after initial filing)

Total Number Of Pages In This Submission

7

Application Number	09/928,047
Filing Date	10 August 2001
First Named Inventor	Tom L. CANTOR
Group Art Unit	1614
Examiner Name	To be assigned
Attorney Docket No.	532212000200


## ENCLOSURES (check all that apply)

- Fee Transmittal Form
- Fee Attached
- Amendment / Reply
- After Final
- Affidavits/declarations
- Extension of Time Request
- Express Abandonment Request
- Information Disclosure Statement; form 1449; 2 references
- Certified Copy of Priority Document(s)
- Response to Missing Parts/ Incomplete Application
- Response to Missing Parts under 37 CFR 1.52 or 1.53

Remarks

- Assignment Papers (for an Application)
- Drawing(s)
- Licensing-related Papers
- Petition
- Petition to Convert to a Provisional Application
- Power of Attorney, Revocation Change of Correspondence Address
- Terminal Disclaimer
- Request for Refund
- CD, Number of CD(s):
- After Allowance Communication to Group
- Appeal Communication to Board of Appeals and Interferences
- Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
- Proprietary Information
- Status Letter
- Other Enclosure(s) (please identify below)
- Return postcard

## SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm or Individual Name	Peng Chen Registration No. 43,543
Signature	
Date	October 15, 2002

## CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on October 15, 2002.

Susan B. Lynch

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

sd-97867



PATENT  
Docket No. 532212000200

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231, on October 15, 2002.

Susan B. Lynch

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
TECH CENTER 2900  
OCT 15 2002

In the application of:

Thomas L. CANTOR

Serial No.: 09/928,047

Filing Date: August 10, 2001

For: CYCLASE INHIBITING  
PARATHYROID HORMONE  
ANTAGONISTS OR MODULATORS  
AND OSTEOPOROSIS

Examiner: To be assigned

Group Art Unit: 1614

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. § 1.97

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the document numbers 15 and 53 are submitted herewith. Copies of the remaining references were submitted in an Information Disclosure Statement, directed to related Application Numbers 10 002,818, filed November 2, 2001, and 09-231,422, filed January 14, 1999. This protocol conforms with 37 C.F.R. § 1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- With the application; accordingly, no fee or separate requirements are required.
- Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
  - A fee is required. A check in the amount of \* is enclosed.
  - A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
  - A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee is believed to be due.
- After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
  - A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of \* is enclosed.
  - A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to

charge the cost of such petitions and or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 532212000200. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: October 9, 2002

By:

  
Peng Chen  
Registration No. 43,543

Morrison & Foerster LLP  
3811 Valley Centre Drive,  
Suite 500  
San Diego, California 92130-2332  
Telephone: (858) 720-5117  
Facsimile: (858) 720-5125

Form PTO-1449

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

Docket Number 532212000200

Application Number 09/928,047

Applicant

Thomas L. CANTOR

Filing Date August 10, 2001

Group Art Unit 1614

Mailing Date October 1, 2002

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1		09 231,422				January 14, 1999
	2		09 344,639				June 26, 1999
	3		09 928,047				August 10, 2001
	4		09 636,530				August 10, 2001
	5		09 636,531				August 10, 2000
	6		10/002,818				November 2, 2001
	7		60/224,396				August 10, 2000
	8		09/928,048				August 10, 2001
	9		09/323,606				June 2, 1999
	10.	01/1983	4,369,138	Lindall	260	112.5	
	11.	12/1983	4,423,037	Rosenblatt et al.	424	177	
	12.	04/1985	4,508,828	Lindall et al.	436	500	
	13.	04/1987	4,656,250	Morita et al.	530	324	
	14.	02/2000	6,030,790	Adermann et al.	435	7.1	
	15.	04/2000	6,051,686	Krstenansky et al.	530	333	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	16.	07 1985	DE 33 47 548	Germany			
	17.	04 1996	DE 44 34 551	Germany			
	18.	12 2001	EP 0 783 522	Europe			
	19.	05 1991	WO 91 06564	PCT			
	20.	04 1993	WO 93 06845	PCT			
	21.	02 1994	WO 94 03201	PCT			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number 532212000200	Application Number 09/128,304
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant	Thomas E. CANFOR
		Filing Date August 10, 2001	Group Art Unit 1614
		Mailing Date October 1, 2002	
22.	04 1996	WO 96 10041	PCT

## OTHER DOCUMENTS


*(including author, title, Date, Pertinent Pages, Etc.)*

Examiner Initials	Ref. No.	Title
	23.	Adermann et al., in: Innovations and Perspectives in Solid Phase Synthesis, Epton (ed.), Mayflower World Wide, Birmingham (1994) pp.429-432
	24.	Atkinson et al., Journal of Immunoassay (1982) 3(1):31-51
	25.	Blind et al., Clin. Chem. (1987) 33(8):1376-1381
	26.	Bowie et al., Science (1990) 247:1306-1310
	27.	Brossard et al., Journal of Clinical Endocrinology and Metabolism (1996) 81(11):3923-3929
	28.	Campbell, Monoclonal Antibody and Immunosensor Technology, in Laboratory Techniques in Biochemistry and Molecular Biology, van der Vliet (ed.), Elsevier (1991) pp.1-11, 42-45
	29.	Caporale and Rosenblatt, Parathyroid Hormone Antagonists Effective in vivo, in: Advances in Experimental Medicine and Biology, New York (1986) pp. 315-327
	30.	Clinical Chemistry (1999) 45(6)Suppl:A97 b, Abstract Nos. 339-341
	31.	D'Amour et al., Am. J. Physiol. (1986) 251:E680-E687
	32.	Daniel et al., Virology (1994) 202:540-549
	33.	Divieti, P. et al. (2001). <i>J Bone Miner Res</i> 2001:Suppl 1, S307.
	34.	Faugere, M.C. et al. (2001). <i>Kidney International</i> 60:1460-1468.
	35.	Faugere, M.C. et al. <i>Nephrology, Bone &amp; Mineral Metabolism</i> A3995.
	36.	Fischer et al., The Journal of Clinical Investigation (1974) 54:1382-1394
	37.	Gao et al., Clinica Chimica Acta (1996) 245:39-59
	38.	Goodman, W. et al. (2000). <i>NEJM</i> 342:20, 1478-1483.
	39.	Gordon et al., Parathyroid Hormone Domain for Protein Kinase C Stimulation Located within Amphiphilic Helix, in: Peptides: Chemistry and Biology, Proceedings of the Twelfth American Peptide Symposium, June 16-21, 1991, Cambridge, MA, Smith and Rivier (eds.) Escom Science Publishers (1992) pp.37-39
	40.	Hashimoto et al., Journal of Cardiovascular Pharmacology (1981) 3(4):668-676
	41.	Hehrmann et al., Journal of Immunoassay (1980) 1(2):151-174
	42.	John et al., Journal of Clinical Endocrinology and Metabolism (1999) 84(11):4287-4290
	43.	LePage et al., Clin. Chem. (1998) 44:805-810

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

Docket Number 532212000200	Application Number 09/928,947
Applicant	Thomas L. CANTOR
Filing Date August 10, 2001	Group Art Unit 1614
Mailing Date October 15, 2002	

44.	Logue et al., Journal of Immunological Methods (1991) 137:159-166
45.	Mägerlein et al., Arzneim.-Forsch. Drug Res. (1998) 48(1):197-204
46.	Mägerlein et al., Arzneim.-Forsch. Drug Res. (1998) 48(II):783-787
47.	Mallette, Journal of Clinical Endocrinology and Metabolism (1980) 50(1):201-203
48.	Nakamura et al., Endocrinol. JPN (1981) 28(4):547-549
49.	Ngo et al., The Protein Folding Problem and Tertiary Structure Prediction, Merz et al., (eds.), Birkhäuser Boston (1994) pp.492-495
50.	Niall et al., Proc. Natl. Acad. Sci. USA (1974) 71(2):384-388
51.	Nussbaum et al., Chemical Abstracts (1982) 96(5):181-192
52.	Pang et al., Pharmacol. Exp. Ther. (1981) 216(3):567-571
53.	Podbesek et al. (1983). Endocrinology 112(3):1000-1006
54.	Qi et al., Am. J. Kidney Dis. (1995) 26:622-631
55.	Quarles et al., J. Clin. Endocrinol. Metab. (1992) 75:145-150
56.	Stadler, Homologous Radioimmunoassay for Human Parathyroid Hormone (Residues 1-34) with Biotinylated Peptide as Tracer, in Calcium Regulating Hormones, Vitamin D Metabolites, and Cyclic AMP Assays and their Clinical Application, Schmidt-Gayk et al., (eds.), Berlin/Heidelberg, Springer, (1990) pp. 137-150
57.	Tampe et al., J. Immunoassay (1992) 13(1):1-13
58.	Visser et al., Acta Endocrinology (1979) 90:90-102
59.	Wingender et al., Structure-Function Relationship in Parathyroid Hormone in: Advances in Protein Design, International Workshop, Blöcker et al. (eds.), VCH (1988) pp.167-176
60.	Zanelli et al., Journal of Immunoassay (1983) 4(2):175-206
61.	Zemplar package insert, Abbott Reference (1998). 06-9998-R1-Rev. Roche Laboratories.

RECEIVED

MAY 11 1998  
TECH CENTER 5629  
2002

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.